对比从未使用胰岛素或胰岛素促泌素糖尿病患者，使用者分别增加了4.99和2.52倍的患病风险。
In contrast, diabetics who had taken insulin or insulin secretagogues had a 4.99 - and 2.52-fold increased risk for the disease, respectively, compared with never users.
胰岛素促泌剂是目前治疗2型糖尿病的一类主要口服降糖药，是非肥胖及部分肥胖2型糖尿病的一线治疗药物。
Insulin secretagogues presently is not only a kind of major oral hypoglycemic drugs but also the first-line treatment for non-obese and obese type 2 diabetic mellitus(T2DM).
胰岛素促泌剂是目前治疗2型糖尿病的一类主要口服降糖药，是非肥胖及部分肥胖2型糖尿病的一线治疗药物。
Insulin secretagogues presently is not only a kind of major oral hypoglycemic drugs but also the first-line treatment for non-obese and obese type 2 diabetic mellitus(T2DM).
应用推荐